NetworkNewsBreaks – PreveCeutical Medical Inc. (
Post# of 77
Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is presently working on the advancement of its Sol-gel drug delivery research program. An article discussing the company reads: “Currently, the company’s research is focused on testing various cannabis strains for the purpose of formulating potent and effective Sol-gels. PreveCeutical Chief Research Officer Dr. Harendra Parekh is leading the program. … In addition, various spray devices have already been tested. According to PreveCeutical CEO and President Stephen Van Deventer, a focus on safety regulations and a tamper-proof delivery system will be of paramount importance. While the Sol-gel program is still in its early phases, the evaluation of delivery systems alongside the cannabis strain testing demonstrates a strong commitment to having a working innovative treatment product on the market.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer